Launch of the consultation on proposed 2021 ABPI Code of Practice for the Pharmaceutical Industry
On Friday 19 June 2020 the ABPI launched a consultation on the proposed changes to the 2019 Association of British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.
The closing date is Tuesday 8 September 2020.
The PMCPA has revised the Code at the request of the ABPI and with its support. The final proposals for the consultation have been agreed by the ABPI and the ABPI Board.
The proposals for the 2021 Code would result in the most significant structural change in nearly 30 years and make a major impact on the way that people interact with the requirements.
Please see 'ABPI Consultation on the proposed 2021 ABPI Code of Practice' under the CODE section of this website, above, for the link to the consultation and access to supporting documents
The Prescription Medicines Code of Practice Authority
The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI. It was established by the ABPI on 1 January 1993.
The Authority is responsible for the provision of advice, guidance and training on the Code as well as for the complaints procedure. It is also responsible for arranging for conciliation between companies when requested to do so and for arranging for the scrutiny of advertising and meetings on a regular basis.
The PMCPA was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry, independently of the ABPI.
The aim of the Code is to ensure that the promotion of medicines by the pharmaceutical industry is carried out within a robust framework, to support high quality patient care.
Code of Practice Seminars
- dates under review. Due to government guidance on COVID-19 the PMCPA has cancelled the Seminar previously scheduled for June 2020 and further dates are subject to change.
ABPI Examination for Medical Representatives
- postponed due to COVID-19. More information is available on the ABPI website, link below
To extend the time available to take the examination and application for an extension should be made on the form on this website, link below
The request should preferably be made by the company rather than the representative.
In house training
- under review due to COVID-19
- unavailable until after the next version of the ABPI Code has been agreed and implemented.
For more information see Training Opportunities.
Otsuka Pharmaceuticals Europe Ltd and Indivior UK limited have been named in advertisements for breaches of the ABPI Code. In addition Otsuka Pharmaceuticals Europe Ltd and AstraZeneca have been publicly reprimanded.
25 June 2020read more
LAUNCH OF ABPI CONSULTATION ON PROPOSALS FOR THE ABPI CODE OF PRACTICE 2021
19 June 2020read more